Travere Therapeutics (Travere Therapeutics) EV-to-EBIT : -1.14 (As of May. 13, 2024)

Travere Therapeutics EV-to-EBIT Chart

Travere Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBIT		Get a 7-Day Free Trial					-3.28	-7.70	-8.36	-4.09	-1.41

Travere Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-4.74	-3.14	-1.28	-1.41	-1.42

Competitive Comparison of Travere Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Travere Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Travere Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Travere Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Travere Therapeutics's EV-to-EBIT falls into.

Travere Therapeutics EV-to-EBIT Calculation

Travere Therapeutics's EV-to-EBIT for today is calculated as:

Travere Therapeutics's current Enterprise Value is $442.6 Mil.
Travere Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-387.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Travere Therapeutics  (NAS:TVTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Travere Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Travere Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $549.8 Mil.
Travere Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-387.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Travere Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Travere Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Travere Therapeutics (Travere Therapeutics) Business Description